Sánchez Cebrián, Juan Domingo

Profile Picture
First Name
Juan Domingo
Last Name
Sánchez Cebrián
Universidad Complutense de Madrid
Faculty / Institute
Química en Ciencias Farmacéuticas
Química Orgánica
UCM identifierORCIDScopus Author IDDialnet IDGoogle Scholar ID

Search Results

Now showing 1 - 3 of 3
  • Publication
    El podcast como recurso didáctico en las asignaturas de Química Orgánica y Farmacéutica en el Grado de Farmacia y doble Grado de Farmacia y Nutrición Humana y dietética
    (2023-07-14) Ruiz Serrano, Miriam; Sánchez Cebrián, Juan Domingo; López-Alvarado Gutiérrez, María Pilar; Ramos García, María Teresa; Villacampa Sanz, Mercedes; Menéndez Ramos, José Carlos; Giorgi Poletti, Giorgio; Sarabia Vallejo, Álvaro; Cores Esperón, Ángel; Clerigué Louzado, José; León Martínez, Rafael; Herrero Gómez, Natalia; Rodríguez Cordero, María Luisa; Solera Viana, María; Cledera Crespo, María Pilar; Polo Parra, Sonia; Rico Arjona, Rocío
    Este proyecto tiene como objetivo la creación, divulgación y uso didáctico de los podcasts como herramienta de difusión de contenidos científicos para el estudio y la profundización de las asignaturas de Química Orgánica y Química Farmacéutica. En este sentido, se pretende que el alumnado, habituado al uso de medios tecnológicos y redes sociales, aprenda a utilizar este recurso no sólo como un instrumento de entretenimiento, sino como un potente medio para el aprendizaje.
  • Publication
    Curcumin-Piperlongumine Hybrids with a Multitarget Profile Elicit Neuroprotection in In Vitro Models of Oxidative Stress and Hyperphosphorylation
    (MDPI, 2021-12-24) Cores Esperón, Ángel; Carmona Zafra, Noelia; Martín Cámara, Olmo; Sánchez Cebrián, Juan Domingo; Duarte, Pablo; Villacampa Sanz, Mercedes; Bermejo Bescos, María De La Paloma; Martín-Aragón Álvarez, Sagrario; León Martínez, Rafael; Menéndez Ramos, José Carlos
    Curcumin shows a broad spectrum of activities of relevance in the treatment of Alzheimer’s disease (AD); however, it is poorly absorbed and is also chemically and metabolically unstable, leading to a very low oral bioavailability. A small library of hybrid compounds designed as curcumin analogues and incorporating the key structural fragment of piperlongumine, a natural neuroinflammation inhibitor, were synthesized by a two-step route that combines a three-component reaction between primary amines, β-ketoesters and α-haloesters and a base-promoted acylation with cinnamoyl chlorides. These compounds were predicted to have good oral absorption and CNS permeation, had good scavenging properties in the in vitro DPPH experiment and in a cellular assay based on the oxidation of dichlorofluorescin to a fluorescent species. The compounds showed low toxicity in two cellular models, were potent inductors of the Nrf2-ARE phase II antioxidant response, inhibited PHF6 peptide aggregation, closely related to Tau protein aggregation and were active against the LPS-induced inflammatory response. They also afforded neuroprotection against an oxidative insult induced by inhibition of the mitochondrial respiratory chain with the rotenone-oligomycin A combination and against Tau hyperphosphorylation induced by the phosphatase inhibitor okadaic acid. This multitarget pharmacological profile is highly promising in the development of treatments for AD and provides a good hit structure for future optimization efforts.
  • Publication
    Advances in the discovery of heterocyclic-based drugs against Alzheimer’s disease
    (Taylor and Francis, 2023-11-01) Sánchez Cebrián, Juan Domingo; Alcántara León, Andrés Rafael; González Matilla, Juan Francisco; Sánchez Montero, José; Sánchez Montero, José
    Introduction Alzheimer’s disease is a multifactorial neurodegenerative disorder characterized by beta-amyloid accumulation and tau protein hyperphosphorylation. The disease involves interconnected mechanisms, which can be clustered into two target-packs based on the affected proteins. Pack-1 focuses on beta-amyloid accumulation, oxidative stress, and metal homeostasis dysfunction, and Pack-2 involves tau protein, calcium homeostasis, and neuroinflammation. Against this background heterocyclic system, there is a powerful source of pharmacophores to develop effective small drugs to treat multifactorial diseases like Alzheimer’s. Areas covered This review highlights the most promising heterocyclic systems as potential hit candidates with multi-target capacity for the development of new drugs targeting Alzheimer’s disease. The selection of these heterocyclic systems was based on two crucial factors: their synthetic versatility and their well-documented biological properties of therapeutic potential in neurodegenerative diseases. Expert opinion The synthesis of small drugs against Alzheimer’s disease requires a multifactorial approach that targets the key pathological proteins. In this context, the utilization of heterocyclic systems, with well-established synthetic processes and facile functionalization, becomes a crucial element in the design phases. Furthermore, the selection of hit heterocyclic should be guided by a full understanding of their biological activities. Thus, the identification of promising heterocyclic scaffolds with known biological effects increases the potential to develop effective molecules against Alzheimer’s disease.